




RealRate

PHARMACEUTICAL 2023

China Pharma Holdings INC
Rank 323 of 471

China Pharma Holdings, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of China Pharma Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of China Pharma Holdings INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 49% points. The greatest weakness of China Pharma Holdings INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 74% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	5,965
Cost of Goods Sold	8,598
Intangible Assets	1,807
Liabilities, Current	12,739
Liabilities, Non-Current	0
Other Assets	39
Other Compr. Net Income	-991
Other Expenses	976
Other Liabilities	755
Other Net Income	-424
Other Revenues	8,104
Property and Equipment	9,973
Research and Development	186
Selling, General and Administrative Expense	1,893

Output Variable	Value in 1000 USD
Assets	17,784
Liabilities	13,494
Expenses	11,653
Revenues	8,104
Stockholders Equity	4,290
Net Income	-3,973
Comprehensive Net Income	-4,468
BaseVar	26,225
ECR before LimitedLiability	31%
Economic Capital Ratio	171%